In preclinical models, CB2 activation reduces neuropathic nociception, provides opioid-sparing effects, and decreases behaviors associated with opioid dependence, including conditioned place preference, self-administration, and withdrawal symptoms [7; 15; 22; 37; 38]. The gene discussed is CNR2; the disease is opiate dependence.